Advertisement

Neurotoxicity Research

, Volume 5, Issue 1–2, pp 147–155 | Cite as

A possible physiological role for cerebral tetrahydroisoquinolines

  • Jerzy Vetulani
  • Lucyna Antkiewicz-Michaluk
  • Irena Nalepa
  • Mario Sansone
Article

Abstract

Tetrahydroisoquinolines present in the mammalian brain, 1,2,3,4-tetrahydroisoquinoline (TIQ) and salsolinol, suspected to cause neurodegeneration leading to Parkinson's disease, were investigated to find their possible physiological role. To this aim their behavioral and receptor effects induced after a single dose were tested in mice and rats. Both compounds do not affect significantly the basal locomotor activity, very effectively block hyperactivity induced by apomorphine (rats) and amphetamine (mice), only partially block hyperactivity induced by scopolamine, do not affect locomotor stimulation induced by cocaine, and strongly augment the running fit induced by morphine (mice). They do not produce extrapyramidal symptoms and do not potentiate haloperidol-induced catalepsy (rats). TIQ and salsolinol do not displace antagonists of several receptors (including D1 and D2) from their binding sites, but displace the agonists of α2-adrenoreceptors, [3H] clonidine and of dopamine receptors, [3H] apomorphine. The results indicate that salsolinol and TIQ act as specific antagonists of agonistic conformation of dopamine receptors, and owing to that may play a role of endogenous feed-back regulators of the dopaminergic system. Those properties make tetrahydroisoquinolines potential antidopaminergic drugs devoid of extrapyramidal effects, with possible application in substance addiction disorder as anti-craving agents.

Keywords

Amphetamine Apomorphine Cocaine Dopamine receptor Hyperactivity Morphine Salsolinol Tetrahydroisoquinolines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antkiewicz-Michaluk L, A Szczudlik, A Krygowska-Wajs, I Romañska and J Vetulani (1997) Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.Biol. Psychiatry 42, 514–518.PubMedCrossRefGoogle Scholar
  2. Antkiewicz-Michaluk L, J Michaluk, I Romanska, I Papla and J Vetulani (2000a) Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.J. Neural Transm. 107, 1009–1019.PubMedCrossRefGoogle Scholar
  3. Antkiewicz-Michaluk L, I Romanska, I Papla, J Michaluk, M Bakalarz, J Vetulani, A Krygowska-Wajs and A Szczudlik (2000b) Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain.Neuroscience 96, 59–64.PubMedCrossRefGoogle Scholar
  4. Antkiewicz-Michaluk L, J Michaluk, M Mokrosz, I Romanska, E Lorenc-Koci, S Ohta and J Vetulani (2001) Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties.J. Neurochem. 78, 100–108.PubMedCrossRefGoogle Scholar
  5. Bednarczyk B and J Vetulani (1977) Stimulatory and inhibitory action of clonidine on the locomotor activity in the rat.Pol J. Pharmacol. Pharm. 29, 219–229.PubMedGoogle Scholar
  6. Cohen G (1976) Alkaloid products in the metabolism of alcohol and biogenic amines.Biochem. Pharmacol. 25, 1123–1128.PubMedCrossRefGoogle Scholar
  7. Deitrich R and V Erwin (1980) Biogenic amine-aldehyde condensation products: tetrahydroisoquinolines and tryptolines (beta-carbolines).Ann. Rev. Pharmacol. Toxicol. 20, 55–80.CrossRefGoogle Scholar
  8. Delini-Stula A and C Morpurgo (1968) Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in rats.Int. J. Neuropharmacol. 7, 391–394.PubMedCrossRefGoogle Scholar
  9. Deng Y, W Maruyama, M Kawai, P Dostert, H Yamamura, T Takahashi and M Naoi (1997) Assay for the (R)- and (S)-enantiomers of salsolinols in biological samples and foods with ion-pair high-performance liquid chromatography using beta-cyclodextrin as a chiral mobile phase additive.J. Chromatogr. B Biomed. Sci. Appl. 689, 313–320.PubMedCrossRefGoogle Scholar
  10. Duncan MW and GA Smythe (1982) Salsolinol and dopamine in alcoholic beverages.Lancet 1, 904–905.PubMedCrossRefGoogle Scholar
  11. Ginos JZ and D Doroski (1979) Dopaminergic antagonists: effects of 1,2,3,4-tetrahydroisoquinoline and itsN-methyl andN-propyl homologs on apomorphine- and L-dopa-induced behavioral effects in rodents.J. Pharmacol. Exp. Ther. 209, 79–86.PubMedGoogle Scholar
  12. Goeders N and J Smith (1983) Cortical dopaminergic involvement in cocaine reinforcement.Science 221, 773–775.PubMedCrossRefGoogle Scholar
  13. Goeders NE and J Smith (1986) Reinforcing properties of cocaine in the medial prefrontal cortex: primary action on presynaptic dopaminergic terminals.Pharmacol. Biochem. Behav. 25, 191–199.PubMedCrossRefGoogle Scholar
  14. Goeders NE, SI Dworkin and JE Smith (1986) Neuropharmacological assessment of cocaine self-administration into the medial prefrontal cortex.Pharmacol. Biochem. Behav. 24, 1429–1440.PubMedCrossRefGoogle Scholar
  15. Hoebel B, A Monaco, L Hernandez, E Aulisi, B Stanley and L Lenard (1983) Self-injection of amphetamine directly into the brain.Psychopharmacology 81, 158–163.PubMedCrossRefGoogle Scholar
  16. Kopin IJ (1987) Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.Adv. Neurol. 45, 137–144.PubMedGoogle Scholar
  17. Lorenc-Koci E, M Smialowska, L Antkiewicz-Michaluk, K Golembiowska, M Bajkowska and S Wolfarth (2000) Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats.Neuroscience 95, 1049–1059.PubMedCrossRefGoogle Scholar
  18. Lowry OH, NJ Rosebrough, AL Farr and RJ Randall (1951) Protein measurement with the Folin phenol reagent.J. Biol. Chem. 193, 265–275.PubMedGoogle Scholar
  19. Maruyama W, G Sobue, K Matsubara, Y Hashizume, P Dostert and M Naoi (1997) A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxy-soquinolinium ion, accumulate in the nigro-striatal system of the human brain.Neurosci. Lett. 223, 61–64.PubMedCrossRefGoogle Scholar
  20. Moser A and D Kompf (1992) Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF.Life Sci. 50, 1885–1891.PubMedCrossRefGoogle Scholar
  21. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease.Neurosci. Res. 29, 99–111.PubMedCrossRefGoogle Scholar
  22. Naoi M, W Maruyama, T Kasamatsu and P Dostert (1998) Oxidation ofN-methyl(R)salsolinol involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines.J. Neural Transm. (Suppl.) 52, 125–138.Google Scholar
  23. Niwa T, N Takeda, N Kaneda, Y Hashizume and T Nagatsu (1987) Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in Parkinsonian and normal human brain.Biochem. Biophys. Res. Commun. 144, 1084–1089.PubMedCrossRefGoogle Scholar
  24. Niwa T, H Yoshizumi, A Tatematsu, S Matsuura and T Nagatsu (1989) Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods.J. Chromatogr. 493, 347–352.PubMedCrossRefGoogle Scholar
  25. Niwa T, N Takeda, H Yoshizumi, A Tatematsu, M Yoshida, P Dostert, M Naoi and T Nagatsu (1991) Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains.Biochem. Biophys. Res. Commun. 177, 603–609PubMedCrossRefGoogle Scholar
  26. Phillips GD, TW Robbins and BJ Everitt (1994) Bilateral intraaccumbens self-administration ofd-amphetamine: antagonism with intra-accumbens SCH-23390 and sulpiride.Psychopharmacology 114, 477–485.PubMedCrossRefGoogle Scholar
  27. Riggin RM, MJ McCarthy and PT Kissinger (1976) Identification of salsolinol as a major dopamine metabolite in the banana.J. Agric. Food Chem. 24, 189–191.PubMedCrossRefGoogle Scholar
  28. Sandler M, S Carter, KR Hunter and GM Stern (1973) Tetrahydroisoquinoline alkaloids:in vivo metabolites of L-dopa in man.Nature 241, 439–443.PubMedCrossRefGoogle Scholar
  29. Sjoquist B, HA Johnson and S Borg (1985) The influence of acute ethanol on the catecholamine system in man as reflected in cerebrospinal fluid and urine. A new condensation product, 1-carboxysalsolinol.Drug Alcohol Depend. 16, 241–249.PubMedCrossRefGoogle Scholar
  30. Strolin Benedetti M, V Bellotti, E Pianezzola, E Moro, P Carminati and P Dostert (1989) Ratio of theR andS enantiomers of salsolinol in food and human urine.J. Neural Transm. 77, 47–53.PubMedCrossRefGoogle Scholar
  31. Tasaki Y, Y Makino, S Ohta and M Hirobe (1993) Biosynthesis of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), a possible antiparkinsonism agent.Adv. Neurol. 60, 231–233.PubMedGoogle Scholar
  32. Vetulani J (1973) The action of neuroleptics in rats with altered catecholamine metabolism. Part I. The influence of MAO inhibitors on the behavioral actions of chlorpromazine, haloperidol and thioridazine.Pol. J. Pharmacol. Pharm. 25, 41–52.PubMedGoogle Scholar
  33. Vetulani J (2001) Drug addiction. Part II. Neurobiology of addiction.Pol J. Pharmacol. 53, 303–317.PubMedGoogle Scholar
  34. Vetulani J, I Nalepa, L Antkiewicz-Michaluk and M Sansone (2001) Opposite effect of simple tetrahydroisoquinolines on amphetamine-and morphine-stimulated locomotor activity in mice.J. Neural Transm. 108, 513–526.PubMedCrossRefGoogle Scholar
  35. Weiner H (1981) Possible steady-state concentrations of tetrahydroisoquinolines in brain after the consumption of ethanol.Fed. Proc. 40, 2082–2085.PubMedGoogle Scholar
  36. Yamakawa T, Y Kotake, M Fujitani, H Shintani, Y Makino and S Ohta (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain.Neurosci. Lett. 276, 68–70.PubMedCrossRefGoogle Scholar
  37. Zarranz de Ysern ME and LA Ordonez (1981) Tetrahydroisoquinolines: a review.Progr. Neuropsychopharmacol. 5, 343–355.CrossRefGoogle Scholar

Copyright information

© Springer 2003

Authors and Affiliations

  • Jerzy Vetulani
    • 1
  • Lucyna Antkiewicz-Michaluk
    • 1
  • Irena Nalepa
    • 1
  • Mario Sansone
    • 2
  1. 1.Institute of PharmacologyP.A.N.KrakówPoland
  2. 2.Istituto di Psicobiologia e PsicofarmacologiaC.N.R.RomaItaly

Personalised recommendations